News Releases :: Sutro Biopharma, Inc. (STRO)

Jun 3, 2023 4:00 pm EDT

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

May 31, 2023 8:00 am EDT

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

May 15, 2023 8:00 am EDT

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

May 8, 2023 8:00 am EDT

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Apr 27, 2023 4:30 pm EDT

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Apr 18, 2023 1:30 pm EDT

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

Mar 30, 2023 4:30 pm EDT

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Mar 17, 2023 4:01 pm EDT

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 1, 2023 8:00 am EST

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference

Feb 28, 2023 8:00 am EST

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer